Alefacept
Genetically engineered immunosuppressive drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Alefacept?
Summarize this article for a 10 year old
Alefacept is a genetically engineered immunosuppressive drug. It was sold under the brand name Amevive in Canada, the United States, Israel, Switzerland and Australia. In 2011, the manufacturers made a decision to cease promotion, manufacturing, distribution and sales of Amevive during a supply disruption. According to Astellas Pharma US, Inc.,[1] the decision to cease Amevive sales was neither the result of any specific safety concern nor the result of any FDA-mandated or voluntary product recall. On the other hand, usage of Amevive was associated with a certain risk of development systemic diseases such as malignancies. This drug was never approved for the European drug market.
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a603011 |
Pregnancy category |
|
Routes of administration | Intravenous, intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 63% (IM) |
Elimination half-life | ~270 hours |
Identifiers | |
| |
CAS Number | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
Chemical and physical data | |
Formula | C2306H3594N610O694S26 |
Molar mass | 51801.25 g·mol−1 |
NY (what is this?) (verify) |
Alefacept is used to control inflammation in moderate to severe psoriasis with plaque formation, where it interferes with lymphocyte activation.[2] It is also being studied in the treatment of cutaneous T-cell lymphoma and T-cell non-Hodgkin lymphoma.[3]
Alefacept is a fusion protein: it combines part of an antibody with a protein that blocks the growth of some types of T cells.[3]